1. |
Poo MM, Szaflarski JP, Dworetzky BA, et al. China brain project:basic neuroscience, brain diseases, and brain-inspired computing. Neuron, 2016, 92(3):591-596.
|
2. |
Pitkanen A, Diaz FJ, Krebill R, et al. Advances in the development of biomarkers for epilepsy. Lancet Neurol, 2016, 15(8):843-856.
|
3. |
Pauline Anderson. New ILAE classification system for seizures. Medscape, 2016, 33(12):301-310.
|
4. |
Privitera MD, Welty TE, Gidal BE, et al. Generic-to-generic lamotrigine switches in people with epilepsy:the randomised controlled EQUIGEN trial. Lancet Neurol, 2016, 15(3):365-372.
|
5. |
Kesselheim AS, Kahane P, Ryvlin P, et al. Switching generic antiepileptic drug manufacturer not linked to seizures:a case-crossover study. Neurology, 2016, 87(10):1796-1801.
|
6. |
French JA, Chabardès S, Isnard J, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3):a phase 3, randomised, double-blind, placebo-controlled study. Lancet, 2016, 388(4):2153-2163.
|
7. |
Marguet SL, Guénot M, Hoffmann D, et al. Treatment during a vulnerable developmental period rescues a genetic epilepsy. Nat Med, 2015, 21(8):1436-1444.
|
8. |
Barba C, Rheims S, Minotti L, et al. Temporal plus epilepsy is a major determinant of temporal lobe surgery failures. Brain, 2016, 139(4):444-451.
|
9. |
Bernhardt BC, Lew S, Oijala M, et al. Magnetic resonance imaging pattern learning in temporal lobe epilepsy:classification and prognostics. Ann Neurol, 2015, 77(3):436-446.
|
10. |
Krook-Magnuson E, Armstrong C, Bui A, et al. In vivo evaluation of the dentate gate theory in epilepsy. J Physiol, 2015, 593(10):2379-8238.
|
11. |
Chen Z, Liew D, Kwan P. Real-world cost-eff ectiveness of pharmacogenetic screening for epilepsy treatment. Neurology, 2016, 86(10):1086-1094.
|